$ABCL is down big on the news that Merck's new drug reduces hospitalization by 50%
Same with the recent ipo
$HLTH which produces the home testing assay and reader/mobile app that came out at $16 rocketed to $21, and now way below the IPO price.
I would expect the market to sell off these other stocks on this news, but feels way overdone to me.
Abcellera has other programs besides COVID, and same with
$HLTH testing platform.